Legal protection of intellectual property rights over naturally occurring or artificially modified genetic sequences. Debate involves the balance between incentivizing research investment and ensuring broad access to genetic information for medical and scientific progress.
Without patent protection, companies would be unable to recoup the enormous investment required to identify, characterize, and develop clinically useful genetic insights. Patents enable the private investment that has produced many diagnostic and therapeutic advances.
Basic genetic sequences are discoveries of nature rather than inventions. Patenting them does not reward creative invention but appropriates natural information that should be available to all researchers, potentially slowing downstream innovation more than it stimulates it.
Patent holders who license their genetic intellectual property broadly enable wide access while recovering development costs. License revenue can also fund continued research into rarer conditions where commercial returns are insufficient without IP protection.
The BRCA1/2 gene patents held by Myriad Genetics exemplify the problem: exclusive ownership of diagnostically crucial genes allowed a single company to set prices, block independent research, and restrict second-opinion testing, directly harming patient outcomes.
Gene patents with research exemptions preserve the scientific commons for academic researchers while allowing commercial exploitation of practical applications. The framework can be calibrated to protect investment without blocking fundamental scientific inquiry.
Patent thickets — overlapping claims on related genetic sequences — create a minefield for researchers who cannot pursue therapeutic leads without costly licensing negotiations. The aggregate effect of multiple overlapping gene patents on research programs can be severely inhibitory.
Patent law already distinguishes between naturally occurring materials and engineered modifications, restricting protection to the latter. This framework appropriately rewards human inventive work while leaving natural genetic information in the public domain.
Genetic sequences carry information about individuals and their families, not just about abstract biological systems. Allowing corporate ownership of this information raises profound ethical questions about sovereignty over one's biological heritage that patent law is poorly equipped to address.